Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics

Abd El-Rehim,Dalia Mohamed; Abd El-Maqsoud,Nehad Mohamed Reda; Abd El-Hamid,Amr Mohamed; Fath El-bab,Tarek Khalaf; Galal,Ehab Mohamed

doi:10.3892/mco.2013.57

Expression of extracellular matrix metalloproteinase inducer and fascin in urinary bladder cancer: Correlation with clinicopathological characteristics

Authors:
- Dalia Mohamed Abd El-Rehim
- Nehad Mohamed Reda Abd El-Maqsoud
- Amr Mohamed Abd El-Hamid
- Tarek Khalaf Fath El-bab
- Ehab Mohamed Galal
View Affiliations

Affiliations: Department of Pathology, Faculty of Medicine, Minia University, Minia 61111, Egypt, Department of Urology, Faculty of Medicine, Minia University, Minia 61111, Egypt
Published online on: January 2, 2013 https://doi.org/10.3892/mco.2013.57
Pages: 297-304

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Expression of extracellular matrix metalloproteinase inducer (EMMPRIN) and fascin have recently received considerable attention as emerging key markers of cell invasion and metastasis in various types of cancers. The present study aimed to characterize the expression of EMMPRIN and fascin in a cohort of bladder cancer patients and to verify the association with clinicopathological characteristics. Immunohistochemical analysis of EMMPRIN and fascin was performed in 125 bladder cancer specimens, including 86 transitional cell carcinoma (TCC) and 39 squamous cell carcinoma (SCC) cases. Overexpression of EMMPRIN and fascin was detected in 71.2 and 83.2% of bladder carcinomas, respectively, while neither was detectable in the normal adjacent epithelium. In SCC, EMMPRIN and fascin expression scores were found to be higher compared to TCC cases (P=0.031 and 0.053, respectively). Higher EMMPRIN and fascin immunoscores markedly correlated with tumor pathological (pT) stage in TCC (P<0.001) and SCC (P=0.004 and 0.001, respectively). High EMMPRIN expression was strongly associated with advanced grades in TCC and SCC (P=0.003 and 0.002, respectively). Cases were then stratified, according to the joint expression status of EMMPRIN and fascin, into four immunoprofiles. A highly significant association was found between various tumor immunoprofiles and pathological stage. Of those, the EMMPRIN‑/fascin-positive immunophenotype was closely associated with pT3 and pT4 tumors. The findings suggested an association between increased EMMPRIN and fascin expression and increased progression of bladder cancer. Additionally, these two markers may act in concert to mediate a more aggressive behavior through enhanced tumor cell invasion.

View Figures

View References

1	Ploeg M, Aben KK and Kiemeney LA: The present and future burden of urinary bladder cancer in the world. World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
2	Salem HK and Mahfouz S: Changing patterns (age, incidence, and pathologic types) of schistosoma-associated bladder cancer in Egypt in the past decade. Urology. 79:379–383. 2012. View Article : Google Scholar : PubMed/NCBI
3	Mokhtar N, Gouda I and Adel I: Cancer pathology registry 2003–2004 and time trend analysis NCI. El Sheraa Press; Cairo: 2007
4	Cheng L, Montironi R, Davidson DD and Lopez-Beltran A: Staging and reporting of urothelial carcinoma of the urinary bladder. Mod Pathol. 22(Suppl 2): 70–95. 2009. View Article : Google Scholar : PubMed/NCBI
5	Als AB, Dyrskjøt L, von der Maase H, et al: Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer. Clin Cancer Res. 13:4407–4414. 2007. View Article : Google Scholar : PubMed/NCBI
6	Yan L, Zucker S and Toole BP: Roles of the multifunctional glycoprotein, emmprin (basigin; CD147), in tumour progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
7	Han ZD, Bi XC, Qin WJ, et al: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res. 15:369–374. 2009. View Article : Google Scholar : PubMed/NCBI
8	Huang Z, Huang H, Li H, et al: EMMPRIN expression in tongue squamous cell carcinoma. J Oral Pathol Med. 38:518–523. 2009. View Article : Google Scholar : PubMed/NCBI
9	Yu W, Liu J, Xiong X, et al: Expression of MMP9 and CD147 in invasive squamous cell carcinoma of the uterine cervix and their implication. Pathol Res Pract. 205:709–715. 2009. View Article : Google Scholar : PubMed/NCBI
10	Zhu S, Li Y, Mi L, et al: Clinical impact of HAb18G/CD147 expression in esophageal squamous cell carcinoma. Dig Dis Sci. 56:3569–3576. 2011. View Article : Google Scholar : PubMed/NCBI
11	Hashimoto Y, Skacel M and Adams JC: Roles of fascin in human carcinoma motility and signaling: prospects for a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Xu L, Xiao D, et al: Fascin is a potential biomarker for early-stage oesophageal squamous cell carcinoma. J Clin Pathol. 59:958–964. 2006. View Article : Google Scholar : PubMed/NCBI
13	Darnel AD, Behmoaram E, Vollmer RT, et al: Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer. Clin Cancer Res. 15:1376–1383. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lin CK, Chao TK, Yu CP, et al: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS. 117:162–175. 2009. View Article : Google Scholar : PubMed/NCBI
15	Zhong WD, Chen QB, Ye YK, et al: Extracellular matrix metalloproteinase inducer expression has an impact on survival in human bladder cancer. Cancer Epidemiol. 34:478–482. 2010. View Article : Google Scholar : PubMed/NCBI
16	Han ZD, He HC, Bi XC, et al: Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res. 160:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
17	Afonso J, Longatto-Filho A, Baltazar F, et al: CD147 overexpression allows an accurate discrimination of bladder cancer patients’ prognosis. Eur J Surg Oncol. 37:811–817. 2011.PubMed/NCBI
18	Wittschieber D, Stenzinger A, Klauschen F, et al: Decreased RECK and increased EMMPRIN expression in urothelial carcinoma of the bladder are associated with tumor aggressiveness. Pathobiology. 78:123–131. 2011. View Article : Google Scholar : PubMed/NCBI
19	Karasavvidou F, Barbanis S, Pappa D, et al: Fascin determination in urothelial carcinomas of the urinary bladder: a marker of invasiveness. Arch Pathol Lab Med. 132:1912–1915. 2008.PubMed/NCBI
20	Bi J, Chen X, Zhang Y, et al: Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder. Urol Oncol. 30:688–694. 2010. View Article : Google Scholar : PubMed/NCBI
21	McKnight R, Cohen C and Siddiqui MT: Fascin stain as a potential marker of invasiveness in carcinomas of the urinary bladder: a retrospective study with biopsy and cytology correlation. Diagn Cytopathol. 39:635–640. 2011. View Article : Google Scholar : PubMed/NCBI
22	Xie JJ, Xu LY, Zhang HH, et al: Role of fascin in the proliferation and invasiveness of esophageal carcinoma cells. Biochem Biophys Res Commun. 337:355–362. 2005. View Article : Google Scholar : PubMed/NCBI
23	Eble JN, Sauter G, Epstein JI and Sesterhenn IA: World Health Organization classification of tumors. Pathology and genetics of tumors of the urinary system and male genital organs. IARC Press; Lyon: pp. 90–109. 2004
24	Takikita M, Hu N, Shou JZ, et al: Fascin and CK4 as biomarkers for esophageal squamous cell carcinoma. Anticancer Res. 31:945–952. 2011.PubMed/NCBI
25	Jayo A and Parsons M: Fascin: a key regulator of cytoskeletal dynamics. Int J Biochem Cell Biology. 42:1614–1617. 2010. View Article : Google Scholar : PubMed/NCBI
26	Tong GX, Yee H, Chiriboga L, et al: Fascin-1 expression in papillary and invasive urothelial carcinomas of the urinary bladder. Hum Pathol. 36:741–746. 2005. View Article : Google Scholar : PubMed/NCBI
27	Blaveri E, Simko JP, Korkola JE, et al: Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 11:4044–4055. 2005. View Article : Google Scholar : PubMed/NCBI
28	Shokeir AA: Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment. BJU int. 93:216–220. 2004. View Article : Google Scholar : PubMed/NCBI
29	Tsai WC, Sheu LF, Nieh S, et al: Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters. World J Urol. 25:73–80. 2007. View Article : Google Scholar : PubMed/NCBI
30	Jung EJ, Lee JH, Min BW, et al: Clinicopathologic significance of fascin, extracellular matrix metalloproteinase inducer, and ezrin expressions in colorectal adenocarcinoma. Indian J Pathol Microbiol. 54:32–36. 2011. View Article : Google Scholar